AR091090A1 - Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas - Google Patents

Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas

Info

Publication number
AR091090A1
AR091090A1 ARP130101729A ARP130101729A AR091090A1 AR 091090 A1 AR091090 A1 AR 091090A1 AR P130101729 A ARP130101729 A AR P130101729A AR P130101729 A ARP130101729 A AR P130101729A AR 091090 A1 AR091090 A1 AR 091090A1
Authority
AR
Argentina
Prior art keywords
small cell
treatment
human patient
nucleotides
metastatic
Prior art date
Application number
ARP130101729A
Other languages
English (en)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR091090A1 publication Critical patent/AR091090A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona los métodos para el tratamiento de un paciente humano quien padece cáncer de pulmón de células no pequeñas metastásico o avanzado, no resecable, cuyos métodos comprenden administrar periódicamente al paciente humano quimioterapia que comprende una cantidad de docetaxel y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCTTCATCAT (Seq. ID Nº 1), donde el oligonucleótido anti-clusterina tiene una columna vertebral fósforotioato a su través, tiene mitades de azúcar de los nucleótidos 1 - 4 y 18 - 21 que portan modificaciones 2-O-metoxietilo, tiene los nucleótidos 5 - 17 que son 2desoxinucleótidos y tiene 5-metilcitosinas en los nucleótidos 1, 4 y 19, tratando así al paciente humano que padece de cáncer de pulmón de célula no pequeña metastásico o avanzado, no resecable. También proporciona composiciones y combinaciones, paquetes y usos de los mismos para el tratamiento de un paciente humano que padece de cáncer de pulmón de célula no pequeña metastásico o avanzado, no resecable.
ARP130101729A 2012-05-18 2013-05-17 Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas AR091090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
AR091090A1 true AR091090A1 (es) 2014-12-30

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101729A AR091090A1 (es) 2012-05-18 2013-05-17 Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (es)
EP (1) EP2849761A1 (es)
JP (1) JP2015522542A (es)
KR (1) KR20150024843A (es)
CN (1) CN104684564A (es)
AR (1) AR091090A1 (es)
AU (1) AU2013262589A1 (es)
BR (1) BR112014028787A2 (es)
CA (1) CA2874092A1 (es)
EA (1) EA201492148A1 (es)
IL (1) IL235459A0 (es)
IN (1) IN2014DN10390A (es)
PH (1) PH12014502569A1 (es)
SG (1) SG11201407649RA (es)
TW (1) TW201402132A (es)
UY (1) UY34812A (es)
WO (1) WO2013173757A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2011143071A2 (en) 2010-05-08 2011-11-17 The Regents Of The University Of California Sem scanner sensing apparatus, system and methodology for early detection of ulcers
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
AU2018217187B2 (en) 2017-02-03 2020-01-02 Bruin Biometrics, Llc Measurement of edema
GB2600266B (en) 2017-02-03 2023-03-01 Bruin Biometrics Llc Measurement of tissue viability
KR102283395B1 (ko) 2017-02-03 2021-07-30 브루인 바이오메트릭스, 엘엘씨 당뇨병성 족부 궤양에 대한 감수성의 측정
WO2019099812A1 (en) * 2017-11-16 2019-05-23 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
CA3090395A1 (en) 2018-02-09 2019-08-15 Bruin Biometrics, Llc Detection of tissue damage
LT3861601T (lt) 2018-10-11 2024-03-12 Bruin Biometrics, Llc Prietaisas su vienkartiniu elementu
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
JP2014520081A (ja) * 2011-05-19 2014-08-21 テバ ファーマシューティカル インダストリーズ リミティド 非小細胞肺癌を処置するための方法

Also Published As

Publication number Publication date
TW201402132A (zh) 2014-01-16
PH12014502569A1 (en) 2015-01-21
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
JP2015522542A (ja) 2015-08-06
CA2874092A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
AU2013262589A1 (en) 2015-01-22
EA201492148A1 (ru) 2015-04-30
IN2014DN10390A (es) 2015-08-14
UY34812A (es) 2013-12-31
WO2013173757A8 (en) 2015-04-30
IL235459A0 (en) 2014-12-31
KR20150024843A (ko) 2015-03-09

Similar Documents

Publication Publication Date Title
AR091090A1 (es) Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas
AU2018256508A1 (en) Individualized vaccines for cancer
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
BRPI1013957A2 (pt) método para produzir exossomas moduladores imunes específicos, composição farmacêutica, exossoma, e, método para tratar um indivíduo em necessidade do tratamento.
EP3800255A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
AR086514A1 (es) Metodo de tratamiento del cancer de pulmon de celulas no pequeñas, composicion, uso, envase
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX2014012381A (es) Terapia de combinacion para tratar cancer.
SA519401379B1 (ar) علاج فيروس مرتبط بغدة لمرض هنتنجتون
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
MX359548B (es) Agentes de iarn modificados.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2011009751A (es) Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2012054723A3 (en) Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
EP2700708A3 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
MX2011009752A (es) Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
WO2011091390A3 (en) Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
EA201590070A1 (ru) ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
WO2011109422A8 (en) Compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure